CRA Life Sciences experts Tim Wilsdon, Michele Pistollato, Antun Sablek, and Qinyi Wang contributed to a research article titled “The unexploited potential of data systems tracking medicines utilization: An opportunity to improve access to oncology combination therapies“ published in Frontiers in Pharmacology.
The study examines how data systems in Belgium, England, France, Italy, Spain, Sweden, Switzerland, and Australia could be better leveraged to support access to oncology combination therapies – an area where patients often face delays due to pricing and reimbursement challenges.
The authors’ review of national data systems revealed that while most countries already collect medicine utilization data, these systems often lack the granularity needed to distinguish between monotherapies and combinations. Without this capability, innovative pricing models such as combination-specific pricing remain difficult to implement.
The study concludes that optimizing existing data infrastructures, rather than building new ones, could unlock more equitable access to these advanced cancer treatments.
Read the full article here.
